Lenira-Mist Syrup is a combination pharmaceutical formulation containing Ambroxol (30mg/5ml), Levosalbutamol (1mg/5ml), and Guaifenesin (50mg/5ml), designed for the symptomatic management of respiratory conditions characterized by productive cough and bronchial congestion. Ambroxol acts as a mucolytic agent, facilitating the breakdown and clearance of mucus from the respiratory tract, thereby improving airway patency. Levosalbutamol, a selective β2-adrenergic receptor agonist, provides bronchodilation by relaxing bronchial smooth muscle, which aids in relieving bronchospasm and improving airflow in obstructive airway diseases such as asthma and chronic obstructive pulmonary disease (COPD). Guaifenesin serves as an expectorant, promoting the loosening and thinning of mucus, which enhances expectoration and reduces cough frequency and intensity. Lenira-Mist Syrup is indicated for the treatment of acute and chronic respiratory tract disorders including bronchitis, asthma exacerbations, and other conditions involving viscous mucus and bronchospasm. The syrup formulation allows for ease of administration, particularly in pediatric and geriatric populations. Dosage and duration of therapy should be determined by a healthcare professional based on individual patient needs and clinical response. Caution is advised in patients with hypersensitivity to any component and in those with cardiovascular disorders.